Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Loading up?

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Nov 08, 2022 8:07am

92 Views

Post# 35081289

RE:RE:RE:Loading up?

I remember CFO saying it was the same SKU. So using the same pre-existing inventory just prepared differently.

SPCEO1 wrote: It likely includes TH building their inventories of IV Push. But Bloomberg's weekly sales estimator also suggests the introduction of IV Push had a positive impact on October's Trogarzo sales. Not that positive but a nice percentage increase. Unfortunately, Bloomberg's estimates have been dubious in the past so it could be better or worse than how it appears.

qwerty22 wrote: Hard to see it being actual drug sales to patients. Some other revenue realized. Say selling THTX shares. Can that be classed as revenue from Trogarzo?